Physician profile
Manish Garg
NPI 1821035650
$981.12
in general payments reported to CMS, 2019-2025
18 companies · $93.29 in 2025
The $93.29 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $134 · 2021: $50.35 · 2022: $30.42 · 2023: $97.62 · 2024: $246 · 2025: $93.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $416 · Education: $20.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.32 |
| Education | $20.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $126.59 | 2020-2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $115.93 | 2024 | Xphozah 30 Mg |
| Amgen INC. | $109.44 | 2019-2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $107.36 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $89.93 | 2019-2023 | Lokelma |
| Fresenius USA Marketing, INC. | $76.13 | 2019-2023 | Velphoro |
| Horizon Therapeutics Plc | $72.43 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $56.78 | 2020-2025 | Rayaldee |
| Vifor Pharma, INC. | $47.61 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $41.23 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.94 | 2023 | |
| Covidien LP | $26.16 | 2020 | |
| Alexion Pharmaceuticals, INC. | $18.66 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.97 | 2019 | |
| Glaxosmithkline, LLC. | $13.82 | 2023 | Benlysta, Jesduvroq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $12.81 | 2021 | |
| Medtronic, INC. | $12.25 | 2022 | |
| Travere Therapeutics, INC. | $3.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.